These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 19203897)
1. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Langerak A; River G; Mitchell E; Cheema P; Shing M Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Saif MW; Kaley K; Chu E; Copur MS Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847 [TBL] [Abstract][Full Text] [Related]
3. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
5. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Saif MW; Peccerillo J; Potter V Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300 [TBL] [Abstract][Full Text] [Related]
6. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Heun J; Holen K Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202 [TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Wong SF Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976 [TBL] [Abstract][Full Text] [Related]
8. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985 [TBL] [Abstract][Full Text] [Related]
9. Role of panitumumab in the management of metastatic colorectal cancer. Saif MW; Cohenuram M Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167 [TBL] [Abstract][Full Text] [Related]
10. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients]. Smith D; Bosacki C; Merrouche Y Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. Hecht JR; Mitchell E; Chidiac T; Scroggin C; Hagenstad C; Spigel D; Marshall J; Cohn A; McCollum D; Stella P; Deeter R; Shahin S; Amado RG J Clin Oncol; 2009 Feb; 27(5):672-80. PubMed ID: 19114685 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab. Brugger W Tumori; 2010; 96(3):473-7. PubMed ID: 20845811 [TBL] [Abstract][Full Text] [Related]
14. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Giusti RM; Cohen MH; Keegan P; Pazdur R Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350 [TBL] [Abstract][Full Text] [Related]
15. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience. van Hellemond IE; Creemers GJ; van Warmerdam LJ; de Jong FA; Koornstra RH Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):135-41. PubMed ID: 24246276 [TBL] [Abstract][Full Text] [Related]
16. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Cartwright TH; Genther R Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639 [TBL] [Abstract][Full Text] [Related]
17. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. Pettigrew M; Kavan P; Surprenant L; Lim HJ J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575 [TBL] [Abstract][Full Text] [Related]
18. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Blick SK; Scott LJ Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592 [TBL] [Abstract][Full Text] [Related]
19. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547 [TBL] [Abstract][Full Text] [Related]